25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ANTX (AN2 Therapeutics Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze AN2 Therapeutics Inc together

I guess you are interested in AN2 Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – AN2 Therapeutics Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – AN2 Therapeutics Inc’s Price Targets

I'm going to help you getting a better view of AN2 Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about AN2 Therapeutics Inc

I send you an email if I find something interesting about AN2 Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of AN2 Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of AN2 Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
23.1%

What is your share worth?

Current worth
$2.72
Expected worth in 1 year
$1.30
How sure are you?
30.8%

+ What do you gain per year?

Total Gains per Share
$-1.42
Return On Investment
-101.7%

For what price can you sell your share?

Current Price per Share
$1.40
Expected price per share
$1.29 - $1.675
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of AN2 Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
$1.40
Intrinsic Value Per Share
$-5.58 - $-6.06
Total Value Per Share
$-2.86 - $-3.34

2.2. Growth of AN2 Therapeutics Inc (5 min.)




Is AN2 Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$81.8m$108.4m-$13.8m-14.7%

How much money is AN2 Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$12.8m-$16m$3.1m24.7%
Net Profit Margin-5,192.8%-5,280.6%--

How much money comes from the company's main activities?

2.3. Financial Health of AN2 Therapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of AN2 Therapeutics Inc?

Welcome investor! AN2 Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of AN2 Therapeutics Inc.

First you should know what it really means to hold a share of AN2 Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of AN2 Therapeutics Inc is $1.4. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of AN2 Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in AN2 Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.72. Based on the TTM, the Book Value Change Per Share is $-0.36 per quarter. Based on the YOY, the Book Value Change Per Share is $0.24 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of AN2 Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.25-17.9%-0.43-30.4%-0.54-38.4%-0.43-30.4%-0.43-30.4%
Usd Book Value Change Per Share-0.19-13.8%-0.36-25.4%0.2417.4%0.2114.9%0.2114.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.011.0%0.011.0%
Usd Total Gains Per Share-0.19-13.8%-0.36-25.4%0.2417.4%0.2215.9%0.2215.9%
Usd Price Per Share1.38-1.96-13.74-8.66-8.66-
Price to Earnings Ratio-1.38--1.15--6.32--5.01--5.01-
Price-to-Total Gains Ratio-7.13--5.59--2.03--0.85--0.85-
Price to Book Ratio0.51-0.60-3.74-2.41-2.41-
Price-to-Total Gains Ratio-7.13--5.59--2.03--0.85--0.85-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.4
Number of shares714
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share-0.360.21
Usd Total Gains Per Share-0.360.22
Gains per Quarter (714 shares)-254.13159.32
Gains per Year (714 shares)-1,016.53637.27
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1017-102740597627
20-2033-20448011951264
30-3050-306112017921901
40-4066-407815923902538
50-5083-509519929873175
60-6099-611223935853812
70-7116-712927941824449
80-8132-814631947795086
90-9149-916335953775723
100-10165-1018039959746360

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.013.00.00.0%0.013.00.00.0%0.013.00.00.0%
Book Value Change Per Share0.04.00.00.0%4.08.00.033.3%4.09.00.030.8%4.09.00.030.8%4.09.00.030.8%
Dividend per Share0.00.04.00.0%3.00.09.025.0%3.00.010.023.1%3.00.010.023.1%3.00.010.023.1%
Total Gains per Share0.04.00.00.0%4.08.00.033.3%4.09.00.030.8%4.09.00.030.8%4.09.00.030.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of AN2 Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.193-0.356+84%0.244-179%0.209-192%0.209-192%
Book Value Per Share--2.7193.144-13%3.604-25%3.060-11%3.060-11%
Current Ratio--8.4269.924-15%8.933-6%14.060-40%14.060-40%
Debt To Asset Ratio--0.1110.099+13%0.101+10%0.209-47%0.209-47%
Debt To Equity Ratio--0.1250.110+14%0.113+11%0.084+50%0.084+50%
Dividend Per Share----0%-0%0.014-100%0.014-100%
Enterprise Value--114916206.000147755948.750-22%504974394.500-77%376587060.333-69%376587060.333-69%
Eps---0.250-0.426+71%-0.538+115%-0.425+70%-0.425+70%
Ev To Ebitda Ratio---3.338-2.851-15%-7.146+114%-7.290+118%-7.290+118%
Ev To Sales Ratio--infinfnan%infnan%infnan%infnan%
Free Cash Flow Per Share---0.175-0.409+134%-0.443+153%-0.371+112%-0.371+112%
Free Cash Flow To Equity Per Share---0.175-0.406+132%0.263-167%0.205-186%0.205-186%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---6.057--------
Intrinsic Value_10Y_min---5.577--------
Intrinsic Value_1Y_max---1.378--------
Intrinsic Value_1Y_min---1.354--------
Intrinsic Value_3Y_max---3.553--------
Intrinsic Value_3Y_min---3.403--------
Intrinsic Value_5Y_max---5.019--------
Intrinsic Value_5Y_min---4.709--------
Market Cap42138180.000+1%41536206.00059068698.750-30%413405644.500-90%260515824.923-84%260515824.923-84%
Net Profit Margin----51.9280%-52.8060%-32.2260%-32.2260%
Operating Margin----109.4250%-58.8560%-51.7790%-51.7790%
Operating Ratio---57.300-100%58.922-100%35.761-100%35.761-100%
Pb Ratio0.515+1%0.5070.604-16%3.736-86%2.405-79%2.405-79%
Pe Ratio-1.400-1%-1.380-1.151-17%-6.315+357%-5.014+263%-5.014+263%
Price Per Share1.400+1%1.3801.963-30%13.735-90%8.655-84%8.655-84%
Price To Free Cash Flow Ratio-1.998-1%-1.969-1.289-35%-7.670+289%-6.300+220%-6.300+220%
Price To Total Gains Ratio-7.237-1%-7.133-5.592-22%-2.031-72%-0.848-88%-0.848-88%
Quick Ratio--14.24916.686-15%14.930-5%22.779-37%22.779-37%
Return On Assets---0.082-0.121+48%-0.138+68%-0.117+43%-0.117+43%
Return On Equity---0.092-0.134+45%-0.153+67%-0.118+28%-0.118+28%
Total Gains Per Share---0.193-0.356+84%0.244-179%0.223-187%0.223-187%
Usd Book Value--81849000.00094618000.000-13%108487750.000-25%92094615.385-11%92094615.385-11%
Usd Book Value Change Per Share---0.193-0.356+84%0.244-179%0.209-192%0.209-192%
Usd Book Value Per Share--2.7193.144-13%3.604-25%3.060-11%3.060-11%
Usd Dividend Per Share----0%-0%0.014-100%0.014-100%
Usd Enterprise Value--114916206.000147755948.750-22%504974394.500-77%376587060.333-69%376587060.333-69%
Usd Eps---0.250-0.426+71%-0.538+115%-0.425+70%-0.425+70%
Usd Free Cash Flow---5273000.000-12314250.000+134%-13322000.000+153%-11153846.154+112%-11153846.154+112%
Usd Free Cash Flow Per Share---0.175-0.409+134%-0.443+153%-0.371+112%-0.371+112%
Usd Free Cash Flow To Equity Per Share---0.175-0.406+132%0.263-167%0.205-186%0.205-186%
Usd Market Cap42138180.000+1%41536206.00059068698.750-30%413405644.500-90%260515824.923-84%260515824.923-84%
Usd Price Per Share1.400+1%1.3801.963-30%13.735-90%8.655-84%8.655-84%
Usd Profit---7522000.000-12830250.000+71%-16004000.000+113%-12604307.692+68%-12604307.692+68%
Usd Revenue---20000.000-100%20000.000-100%12307.692-100%12307.692-100%
Usd Total Gains Per Share---0.193-0.356+84%0.244-179%0.223-187%0.223-187%
 EOD+5 -3MRQTTM+19 -15YOY+12 -225Y+13 -2310Y+13 -23

3.3 Fundamental Score

Let's check the fundamental score of AN2 Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.400
Price to Book Ratio (EOD)Between0-10.515
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than114.249
Current Ratio (MRQ)Greater than18.426
Debt to Asset Ratio (MRQ)Less than10.111
Debt to Equity Ratio (MRQ)Less than10.125
Return on Equity (MRQ)Greater than0.15-0.092
Return on Assets (MRQ)Greater than0.05-0.082
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of AN2 Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.386
Ma 20Greater thanMa 501.413
Ma 50Greater thanMa 1001.256
Ma 100Greater thanMa 2001.286
OpenGreater thanClose1.360
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About AN2 Therapeutics Inc

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Fundamental data was last updated by Penke on 2025-04-04 03:28:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ AN2 Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ AN2 Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of AN2 Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-5,192.8%+5,192.8%
TTM-5,192.8%YOY-5,280.6%+87.8%
TTM-5,192.8%5Y-3,222.6%-1,970.2%
5Y-3,222.6%10Y-3,222.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--109.6%+109.6%
TTM-5,192.8%-186.4%-5,006.4%
YOY-5,280.6%-206.2%-5,074.4%
5Y-3,222.6%-408.8%-2,813.8%
10Y-3,222.6%-526.8%-2,695.8%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ AN2 Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ AN2 Therapeutics Inc to theΒ Biotechnology industry mean.
  • -8.2% Return on Assets means thatΒ AN2 Therapeutics Inc generatedΒ $-0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of AN2 Therapeutics Inc:

  • The MRQ is -8.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -12.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.2%TTM-12.1%+3.9%
TTM-12.1%YOY-13.8%+1.7%
TTM-12.1%5Y-11.7%-0.4%
5Y-11.7%10Y-11.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.2%-14.2%+6.0%
TTM-12.1%-14.6%+2.5%
YOY-13.8%-14.5%+0.7%
5Y-11.7%-15.6%+3.9%
10Y-11.7%-18.0%+6.3%
4.3.1.3. Return on Equity

Shows how efficient AN2 Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ AN2 Therapeutics Inc to theΒ Biotechnology industry mean.
  • -9.2% Return on Equity means AN2 Therapeutics Inc generated $-0.09Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of AN2 Therapeutics Inc:

  • The MRQ is -9.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -13.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.2%TTM-13.4%+4.2%
TTM-13.4%YOY-15.3%+2.0%
TTM-13.4%5Y-11.8%-1.6%
5Y-11.8%10Y-11.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.2%-17.6%+8.4%
TTM-13.4%-18.3%+4.9%
YOY-15.3%-19.1%+3.8%
5Y-11.8%-24.5%+12.7%
10Y-11.8%-26.3%+14.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of AN2 Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient AN2 Therapeutics Inc is operatingΒ .

  • Measures how much profit AN2 Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ AN2 Therapeutics Inc to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of AN2 Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-10,942.5%+10,942.5%
TTM-10,942.5%YOY-5,885.6%-5,056.9%
TTM-10,942.5%5Y-5,177.9%-5,764.6%
5Y-5,177.9%10Y-5,177.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--224.0%+224.0%
TTM-10,942.5%-281.8%-10,660.7%
YOY-5,885.6%-227.6%-5,658.0%
5Y-5,177.9%-393.8%-4,784.1%
10Y-5,177.9%-509.3%-4,668.6%
4.3.2.2. Operating Ratio

Measures how efficient AN2 Therapeutics Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of AN2 Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM57.300-57.300
TTM57.300YOY58.922-1.622
TTM57.3005Y35.761+21.539
5Y35.76110Y35.7610.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.324-2.324
TTM57.3003.189+54.111
YOY58.9223.069+55.853
5Y35.7615.133+30.628
10Y35.7617.046+28.715
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of AN2 Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if AN2 Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 8.43Β means the company has $8.43 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of AN2 Therapeutics Inc:

  • The MRQ is 8.426. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.924. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ8.426TTM9.924-1.498
TTM9.924YOY8.933+0.991
TTM9.9245Y14.060-4.136
5Y14.06010Y14.0600.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.4263.746+4.680
TTM9.9243.897+6.027
YOY8.9334.470+4.463
5Y14.0605.739+8.321
10Y14.0606.099+7.961
4.4.3.2. Quick Ratio

Measures if AN2 Therapeutics Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ AN2 Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Quick Ratio of 14.25Β means the company can pay off $14.25 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of AN2 Therapeutics Inc:

  • The MRQ is 14.249. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 16.686. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ14.249TTM16.686-2.436
TTM16.686YOY14.930+1.756
TTM16.6865Y22.779-6.093
5Y22.77910Y22.7790.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.2493.086+11.163
TTM16.6863.339+13.347
YOY14.9304.295+10.635
5Y22.7795.726+17.053
10Y22.7796.427+16.352
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of AN2 Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of AN2 Therapeutics IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ AN2 Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.11Β means that AN2 Therapeutics Inc assets areΒ financed with 11.1% credit (debt) and the remaining percentage (100% - 11.1%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of AN2 Therapeutics Inc:

  • The MRQ is 0.111. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.099. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.111TTM0.099+0.012
TTM0.099YOY0.101-0.002
TTM0.0995Y0.209-0.110
5Y0.20910Y0.2090.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1110.340-0.229
TTM0.0990.340-0.241
YOY0.1010.318-0.217
5Y0.2090.365-0.156
10Y0.2090.394-0.185
4.5.4.2. Debt to Equity Ratio

Measures ifΒ AN2 Therapeutics Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ AN2 Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 12.5% means that company has $0.13 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of AN2 Therapeutics Inc:

  • The MRQ is 0.125. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.110. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.125TTM0.110+0.015
TTM0.110YOY0.113-0.003
TTM0.1105Y0.084+0.026
5Y0.08410Y0.0840.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1250.399-0.274
TTM0.1100.407-0.297
YOY0.1130.390-0.277
5Y0.0840.430-0.346
10Y0.0840.461-0.377
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings AN2 Therapeutics Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ AN2 Therapeutics Inc to theΒ Biotechnology industry mean.
  • A PE ratio of -1.38 means the investor is paying $-1.38Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of AN2 Therapeutics Inc:

  • The EOD is -1.400. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.380. Based on the earnings, the company is expensive. -2
  • The TTM is -1.151. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.400MRQ-1.380-0.020
MRQ-1.380TTM-1.151-0.229
TTM-1.151YOY-6.315+5.164
TTM-1.1515Y-5.014+3.863
5Y-5.01410Y-5.0140.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.400-1.855+0.455
MRQ-1.380-2.665+1.285
TTM-1.151-3.217+2.066
YOY-6.315-3.253-3.062
5Y-5.014-6.333+1.319
10Y-5.014-7.244+2.230
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of AN2 Therapeutics Inc:

  • The EOD is -1.998. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.969. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.289. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.998MRQ-1.969-0.029
MRQ-1.969TTM-1.289-0.681
TTM-1.289YOY-7.670+6.381
TTM-1.2895Y-6.300+5.012
5Y-6.30010Y-6.3000.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.998-2.442+0.444
MRQ-1.969-3.660+1.691
TTM-1.289-4.202+2.913
YOY-7.670-4.443-3.227
5Y-6.300-8.523+2.223
10Y-6.300-9.739+3.439
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ AN2 Therapeutics Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 0.51 means the investor is paying $0.51Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of AN2 Therapeutics Inc:

  • The EOD is 0.515. Based on the equity, the company is cheap. +2
  • The MRQ is 0.507. Based on the equity, the company is cheap. +2
  • The TTM is 0.604. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.515MRQ0.507+0.007
MRQ0.507TTM0.604-0.097
TTM0.604YOY3.736-3.132
TTM0.6045Y2.405-1.801
5Y2.40510Y2.4050.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.5151.759-1.244
MRQ0.5072.254-1.747
TTM0.6042.426-1.822
YOY3.7362.456+1.280
5Y2.4053.780-1.375
10Y2.4054.271-1.866
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of AN2 Therapeutics Inc.

4.8.1. Institutions holding AN2 Therapeutics Inc

Institutions are holding 45.939% of the shares of AN2 Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-12-31BML Capital Management LLC19.21634.9291574943200
2024-12-31Almitas Capital LLC4.38880.3971131311113131110
2024-12-31Vanguard Group Inc3.462401035947-5580-0.5358
2024-12-31Pfizer Inc2.39070.03817152957152950
2024-12-31Renaissance Technologies Corp1.93780.001257977315597336.8034
2024-12-31Peapod Lane Capital LLC1.93460.79185788255788250
2024-12-31Two Sigma Advisers, LLC1.76570.0017528300407400336.9727
2024-12-31Bank of Montreal1.41070.00034220774220770
2024-12-31BMO Capital Markets Corp.1.41070.00034220774220770
2024-12-31Two Sigma Investments LLC1.3380.0012400332222492125.108
2024-12-31Bank of Nova Scotia1.31980.0013948683948680
2024-12-31Bank of America Corp1.288403854753692652278.0074
2024-12-31Aldebaran Capital LLC1.14870.4508343684243184241.9741
2024-12-31Adage Capital Partners Gp LLC1.04480.000831261500
2024-12-31BlackRock Inc1.007403014212450.0813
2024-12-31Geode Capital Management, LLC0.7614022779676343.4674
2024-12-31Millennium Management LLC0.69980.0001209366-188559-47.3856
2024-12-31Stonepine Capital Management Llc0.65750.21911967321967320
2024-12-31UBS Group AG0.569201702921702920
2024-12-31Bridgeway Capital Management, LLC0.54210.005162200-34800-17.665
Total 48.29486.837614449618+5390531+37.3%

4.9.2. Funds holding AN2 Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-02-28Vanguard Total Stock Mkt Idx Inv2.50820.000174942100
2025-02-28Vanguard Institutional Extnd Mkt Idx Tr0.87660.000326193100
2024-12-31Bridgeway Ultra-Small Company Market0.53980.123416130000
2025-01-31Fidelity Extended Market Index0.38750.0003115776-1758-1.4957
2025-02-28iShares Micro-Cap ETF0.11780.00453521200
2024-12-31Extended Equity Market Fund K0.11150.000333315-459-1.359
2025-01-31Fidelity Total Market Index0.1043031172-87-0.2783
2025-01-31Fidelity Series Total Market Index0.095302846100
2024-12-31Northern Trust Extended Eq Market Idx0.08460.0004252651060172.2927
2024-12-31NT Ext Equity Mkt Idx Fd - L0.08460.0004252651060172.2927
2025-01-31Spartan Extended Market Index Pool E0.07920.00042365217588.0296
2025-01-31Fidelity Nasdaq Composite Index0.06010.00011797200
2024-12-31Vanguard Instl Ttl Stck Mkt Idx Tr0.05780.00011726100
2025-02-28Vanguard Instl Ttl Stk Mkt Idx InstlPls0.05780.00011726100
2024-12-31NT Ext Equity Mkt Idx Fd - NL0.05610.00041675500
2024-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.04440.000413280-219-1.6223
2025-01-31Spartan Total Market Index Pool E0.0355010618870.8261
2024-12-31U.S. Equity Market Fund F0.0260.00017774-4-0.0514
2025-02-28Vanguard U.S. Eq Idx Β£ Acc0.02450733400
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T40.02010.0004602060200
Total 5.37170.13171605045+26540+1.7%

5.3. Insider Transactions

Insiders are holding 22.339% of the shares of AN2 Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-06-21Ra Capital Management, L.p.BUY3027.993748389
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-12-312024-03-312024-06-302024-09-302024-12-31
Depreciation and Amortization  1918,27718,296-2,41615,880-13,6372,243-2,252-9



5.2. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets92,087
Total Liabilities10,238
Total Stockholder Equity81,849
 As reported
Total Liabilities 10,238
Total Stockholder Equity+ 81,849
Total Assets = 92,087

Assets

Total Assets92,087
Total Current Assets86,262
Long-term Assets5,825
Total Current Assets
Cash And Cash Equivalents 21,351
Short-term Investments 62,267
Other Current Assets 2,644
Total Current Assets  (as reported)86,262
Total Current Assets  (calculated)86,262
+/-0
Long-term Assets
Long Term Investments 5,021
Long-term Assets Other 804
Long-term Assets  (as reported)5,825
Long-term Assets  (calculated)5,825
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities10,238
Long-term Liabilities0
Total Stockholder Equity81,849
Total Current Liabilities
Accounts payable 3,317
Other Current Liabilities 6,921
Total Current Liabilities  (as reported)10,238
Total Current Liabilities  (calculated)10,238
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Retained Earnings -205,776
Accumulated Other Comprehensive Income 31
Other Stockholders Equity 287,594
Total Stockholder Equity (as reported)81,849
Total Stockholder Equity (calculated)81,849
+/-0
Other
Cash and Short Term Investments 83,618
Common Stock Shares Outstanding 29,883
Liabilities and Stockholders Equity 92,087
Net Debt -21,351
Net Invested Capital 81,849
Net Working Capital 76,024



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-31
> Total Assets 
0
0
0
65,316
120,503
120,016
110,008
102,560
91,084
98,926
153,808
138,744
121,260
108,481
97,689
92,087
92,08797,689108,481121,260138,744153,80898,92691,084102,560110,008120,016120,50365,316000
   > Total Current Assets 
0
0
0
60,106
119,783
116,877
107,296
98,621
90,316
98,206
126,409
110,507
116,313
107,438
97,689
86,262
86,26297,689107,438116,313110,507126,40998,20690,31698,621107,296116,877119,78360,106000
       Cash And Cash Equivalents 
0
0
0
12,097
82,519
40,616
28,802
27,219
26,709
40,812
32,616
15,647
24,693
26,769
33,504
21,351
21,35133,50426,76924,69315,64732,61640,81226,70927,21928,80240,61682,51912,097000
       Short-term Investments 
0
0
0
46,458
35,835
72,773
75,580
68,840
61,806
54,446
91,202
91,648
89,517
77,771
59,922
62,267
62,26759,92277,77189,51791,64891,20254,44661,80668,84075,58072,77335,83546,458000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
1,400
500
300
0
0
003005001,40000000000000
       Other Current Assets 
0
0
0
1,551
1,429
3,488
2,914
2,562
1,801
2,948
2,591
1,812
2,103
2,898
4,263
2,644
2,6444,2632,8982,1031,8122,5912,9481,8012,5622,9143,4881,4291,551000
   > Long-term Assets 
0
0
0
5,210
720
3,139
2,712
3,939
768
720
27,399
28,237
4,947
1,043
0
5,825
5,82501,0434,94728,23727,3997207683,9392,7123,1397205,210000
       Property Plant Equipment 
0
0
0
0
32
13
73
53
34
13
0
0
0
0
0
0
0000001334537313320000
       Long Term Investments 
0
0
0
3,486
0
2,419
1,992
3,219
0
0
26,356
27,194
3,904
0
0
5,021
5,021003,90427,19426,356003,2191,9922,41903,486000
       Other Assets 
0
0
0
0
720
0
0
0
0
720
0
0
0
0
0
0
00000072000007200000
> Total Liabilities 
0
0
0
112,727
5,093
4,153
4,435
7,188
8,567
11,162
14,839
14,043
10,663
10,127
10,017
10,238
10,23810,01710,12710,66314,04314,83911,1628,5677,1884,4354,1535,093112,727000
   > Total Current Liabilities 
0
0
0
3,395
5,087
4,149
4,432
7,186
8,566
11,161
14,839
14,043
10,663
10,127
10,017
10,238
10,23810,01710,12710,66314,04314,83911,1618,5667,1864,4324,1495,0873,395000
       Short-term Debt 
0
0
0
0
32
13
73
53
34
13
0
0
0
0
0
0
0000001334537313320000
       Accounts payable 
0
0
0
1,063
2,609
1,612
1,440
2,122
3,545
3,131
4,877
2,676
2,433
1,885
1,711
3,317
3,3171,7111,8852,4332,6764,8773,1313,5452,1221,4401,6122,6091,063000
       Other Current Liabilities 
0
0
0
2,332
2,446
2,524
2,919
5,011
4,987
3
5,085
11,367
8,230
8,242
8,306
6,921
6,9218,3068,2428,23011,3675,08534,9875,0112,9192,5242,4462,332000
   > Long-term Liabilities 
0
0
0
109,332
6
4
3
2
1
1
0
0
8,230
8,242
0
0
008,2428,23000112346109,332000
       Other Liabilities 
0
0
0
0
6
4
3
2
0
1
0
0
0
0
0
0
0000001023460000
> Total Stockholder Equity
0
0
0
-47,411
115,410
115,863
105,573
95,372
82,517
87,764
138,969
124,701
110,597
98,354
87,672
81,849
81,84987,67298,354110,597124,701138,96987,76482,51795,372105,573115,863115,410-47,411000
   Common Stock00000000000-120,5030000
   Retained Earnings Total Equity000000-120,850-105,0460-77,881-66,54200000
   Accumulated Other Comprehensive Income 
0
0
0
-27
-158
-360
-541
-374
-175
-119
-122
275
53
-27
112
31
31112-2753275-122-119-175-374-541-360-158-27000
   Capital Surplus 
0
0
0
0
0
182,765
183,995
0
187,738
208,733
0
0
0
0
0
0
000000208,733187,7380183,995182,76500000
   Treasury Stock0000000000000000
   Other Stockholders Equity 
0
0
0
0
51,487
62,749
73,987
185,469
187,738
208,733
276,648
278,881
281,616
283,888
285,926
287,594
287,594285,926283,888281,616278,881276,648208,733187,738185,46973,98762,74951,4870000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-54,554
Operating Income-54,554-54,554
 
Operating Expense (+$)
Research Development40,488
Selling General Administrative14,066
Selling And Marketing Expenses0
Operating Expense54,55454,554
 
Net Interest Income (+$)
Interest Income5,467
Interest Expense-0
Other Finance Cost-0
Net Interest Income5,467
 
Pretax Income (+$)
Operating Income-54,554
Net Interest Income5,467
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-51,321-52,320
EBIT - interestExpense = 0
-51,321
-51,321
Interest Expense0
Earnings Before Interest and Taxes (EBIT)0-51,321
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-51,321
Tax Provision-0
Net Income From Continuing Ops-51,321-51,321
Net Income-51,321
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net-2,234-5,467
 

Technical Analysis of AN2 Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of AN2 Therapeutics Inc. The general trend of AN2 Therapeutics Inc is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine AN2 Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. AN2 Therapeutics Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of AN2 Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.55 < 1.59 < 1.675.

The bearish price targets are: 1.29 > 1.29 > 1.29.

Know someone who trades $ANTX? Share this with them.πŸ‘‡

AN2 Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of AN2 Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

AN2 Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of AN2 Therapeutics Inc. The current macd is 0.04259117.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the AN2 Therapeutics Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for AN2 Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the AN2 Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
AN2 Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAN2 Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of AN2 Therapeutics Inc. The current adx is 28.84.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell AN2 Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
AN2 Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of AN2 Therapeutics Inc. The current sar is 1.51572906.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
AN2 Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of AN2 Therapeutics Inc. The current rsi is 55.39. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 3/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
AN2 Therapeutics Inc Daily Relative Strength Index (RSI) ChartAN2 Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of AN2 Therapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the AN2 Therapeutics Inc price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
AN2 Therapeutics Inc Daily Stochastic Oscillator ChartAN2 Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of AN2 Therapeutics Inc. The current cci is -48.65167785.

AN2 Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAN2 Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of AN2 Therapeutics Inc. The current cmo is 2.87205578.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
AN2 Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAN2 Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of AN2 Therapeutics Inc. The current willr is -55.55555556.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that AN2 Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
AN2 Therapeutics Inc Daily Williams %R ChartAN2 Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of AN2 Therapeutics Inc.

AN2 Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of AN2 Therapeutics Inc. The current atr is 0.07216757.

AN2 Therapeutics Inc Daily Average True Range (ATR) ChartAN2 Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of AN2 Therapeutics Inc. The current obv is -18,690,195.

AN2 Therapeutics Inc Daily On-Balance Volume (OBV) ChartAN2 Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of AN2 Therapeutics Inc. The current mfi is 45.88.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
AN2 Therapeutics Inc Daily Money Flow Index (MFI) ChartAN2 Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for AN2 Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-11-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-15MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-25WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-12-04MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-12-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-11MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-12-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-24CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-27STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-03STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-04RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-05ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-06STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-07MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-10STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-02-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-02CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

AN2 Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of AN2 Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.386
Ma 20Greater thanMa 501.413
Ma 50Greater thanMa 1001.256
Ma 100Greater thanMa 2001.286
OpenGreater thanClose1.360
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of AN2 Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on AN2 Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about AN2 Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about AN2 Therapeutics Inc

I send you an email if I find something interesting about AN2 Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about AN2 Therapeutics Inc.

Receive notifications about AN2 Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.